QuVa Pharma, Inc.

QuVa Pharma, Inc. is a trailblazer in 503B outsourced compounding, providing a comprehensive range of sterile, ready-to-administer injectable products to all 50 states. Founded in 2015, the company prides itself on driving positive change within the 503B industry, prioritizing safety, efficiency, and reliability. With a robust expertise in cGMPs and sterile pharmaceutical manufacturing, QuVa consistently surpasses industry quality and safety standards, maintaining an exemplary FDA compliance record.

Boasting an expansive 340,000 sq ft footprint across five facilities, QuVa's sterile-to-sterile portfolio, leading cGMP processes, and customer-centric services make it the go-to partner for numerous top-tier health systems. Its commitment to transparency and contracted supply arrangements enables hospitals and health systems to better address patient care and operational requirements.

The recent $275.00M Debt Financing investment on 06 May 2021 by Goldman Sachs and Owl Rock Capital underscores QuVa's market value and future potential. As FDA compliance regulations tighten, QuVa's capacity to consistently supply top-tier products gains even more significance, allowing hospitals to allocate more time to patient care and less on compliance concerns. With its renowned reliability and accountability, QuVa Pharma is firmly positioned as a trusted partner for the nation’s leading health systems.